Pathology Laboratory, Department of Pathology and Laboratory Diagnostics, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
Department of Diagnostic Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland;
Anticancer Res. 2020 Dec;40(12):6685-6697. doi: 10.21873/anticanres.14692.
BACKGROUND/AIM: Follicular lymphoma (FL) relapse within 24 months of the first immunochemotherapy (POD24) indicates more precisely poor overall survival and high risk of death. The aim of the study was to assess the potential value of POD24 in FL and describe the enhancer of zeste homolog 2 (EZH2) expression profile, in correlation with clinical/histopathological/immunophenotypical characteristics.
This retrospective single-center study included 75 patients with FL treated under watch and wait (W&W) and immunochemotherapy regimens. All cases were immunohistochemically assessed: assays were performed for EZH2, CD10, BCL6, BCL2, MUM1, MYC and p53.
POD24 was independent of clinical/histopathological/immunohistochemical features and separated patients with inferior outcomes. EZH2 high expression was observed in high/low grade and follicular/diffuse FL patterns. BCL2-negative (p=0.042) and MUM1 (p=0.039), MYC (p<0.001), p53 (p<0.001) - positive cases had significantly higher EZH2 expression.
POD24 is currently the most useful tool for the identification of poor outlook patients. EZH2 is crucial in FL biology, but the value of its protein expression is limited as a prognostic factor.
背景/目的：滤泡性淋巴瘤（FL）在首次免疫化疗后 24 个月内（POD24）复发表明总体生存更差，死亡风险更高。本研究旨在评估 POD24 在 FL 中的潜在价值，并描述 EZH2 表达谱与临床/组织病理学/免疫表型特征的相关性。
这项回顾性单中心研究纳入了 75 例接受观察和等待（W&W）及免疫化疗方案治疗的 FL 患者。所有病例均进行了免疫组织化学评估：进行了 EZH2、CD10、BCL6、BCL2、MUM1、MYC 和 p53 的检测。
POD24 与临床/组织病理学/免疫组织化学特征无关，但可将预后不良的患者区分开来。EZH2 高表达见于高低级别和滤泡性/弥漫性 FL 模式。BCL2 阴性（p=0.042）和 MUM1（p=0.039）、MYC（p<0.001）、p53（p<0.001）阳性病例的 EZH2 表达显著更高。
POD24 是目前识别预后不良患者的最有用工具。EZH2 在 FL 生物学中至关重要，但作为预后因素，其蛋白表达的价值有限。
